C1q-binding ability may indicate the clinical relevance of de novo donor-specific anti-HLA
antibodies (DSA). This study investigated the incidence and risk factors for the appearance …

Donor-specific HLA antibodies (DSA) have an adverse effect on short-term and long-term
lung transplant outcomes. We implemented a perioperative strategy to treat DSA-positive …

Alloantibodies directed against HLA antigens, are a barrier to long-term solid organ allograft
survival. The clinical impact of preformed, donor-directed HLA alloantibodies range from …

The Food and Drug Administration (FDA) held an open public workshop in June 2010 to
discuss the current state of science related to antibody-mediated rejection (AMR) in kidney …

The presence of preformed donor-specific antibodies in transplant recipients increases the
risk of acute antibody-mediated rejection (AMR). Results of an open-label single-arm trial to …

Background Complement fixation by donor-specific HLA antibodies (DSA) is a primary
mechanism for antibody-mediated damage of organ allografts. Using a recently developed …

Complement inhibitors have not been thoroughly evaluated in the treatment of acute
antibody-mediated rejection (ABMR). We performed a prospective, single-arm pilot study to …

Unlike antibody-mediated rejection (AMR) with clinical features, it remains unclear whether
subclinical AMR should be treated, as its effect on allograft loss is unknown. It is also …

Preformed donor‐specific human leukocyte antigen antibodies (DSAs) are considered a
contraindication to the transplantation of most solid organs other than the liver. Conflicting …

Imlifidase recently received early access authorization for highly sensitized adult kidney
transplant candidates with a positive crossmatch against an ABO-compatible deceased …